# Capricor shares surge 94% on FDA rethink of Duchenne drug

2026-08-14T21:23:21+00:00 | World & Diplomacy | Indian Opinion Desk

Corroboration: 1 independent outlet

Capricor Therapeutics shares jumped as much as 94% intraday after the US Food and Drug Administration signalled willingness to review additional data for deramiocel, the company's experimental therapy for Duchenne muscular dystrophy. NDTV Profit reports the surge followed the FDA's indication to consider fresh evidence from the drug's clinical programme. Duchenne muscular dystrophy is a rare genetic disorder causing progressive muscle degeneration. Deramiocel, formerly known as CAP-1002, is a cell therapy being developed for the condition.

## Coverage

- ndtvprofit.com <https://www.ndtvprofit.com/markets/94-intraday-surge-how-fda-rethink-led-to-capricor-shares-record-sky-high-rally-11911431>

Tags: Capricor Therapeutics, deramiocel, Duchenne muscular dystrophy, FDA
Canonical: https://indianopinion.org/capricor-shares-surge-94-on-fda-rethink-of-duchenne-drug/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/capricor-shares-surge-94-on-fda-rethink-of-duchenne-drug/#story-in-brief

Review state: restored archive article, accurate at time of publication, not offered to search indexes.